Weibel E K, Seiffert B D
Pharma Research New Technologies, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Appl Microbiol Biotechnol. 1993 May;39(2):227-34. doi: 10.1007/BF00228611.
Employees of a biotechnological production plant for recombinant interferon alpha-2a have been participating in a 1-year study on occupational hygiene and the resulting biosafety aspects. Most of the employees have been employed in the plant for more than 6 years. Weekly stool samples were analysed for tetracycline (used as selection marker)-resistant coliforms as well as for rDNA (IFN gene) (interferon gene) and for the production organism. Various analytical methods, including the polymerase chain reaction, were applied to show that neither rDNA nor the production organism could be found in any of the stool samples and that there was no change or trend in the gut flora with respect to tetracycline resistance. In addition it could be shown that the tetracycline-resistance gene, as well as the rDNA, are completely inactivated in the course of the production process and thus no further recombination can take place. Blood samples were taken to show that none of the employees had anti-product antibodies.
一家生产重组干扰素α-2a的生物技术工厂的员工参与了一项为期一年的职业卫生及由此产生的生物安全方面的研究。大多数员工已在该工厂工作6年以上。每周对粪便样本进行分析,检测对四环素(用作选择标记)具有抗性的大肠菌群、rDNA(IFN基因)(干扰素基因)以及生产菌株。应用了包括聚合酶链反应在内的各种分析方法,结果表明在任何粪便样本中均未发现rDNA或生产菌株,并且肠道菌群在四环素抗性方面没有变化或趋势。此外,还表明四环素抗性基因以及rDNA在生产过程中完全失活,因此不会再发生进一步的重组。采集血液样本以表明没有员工产生抗产品抗体。